← Back to Search

Procedure

Transcranial Magnetic Stimulation for Brain Tumors

N/A
Waitlist Available
Led By Sarah Prinsloo
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial studies if navigated repetitive transcranial magnetic stimulation can help improve patients' lost motor function after surgery for a brain tumor.

Who is the study for?
This trial is for individuals with brain tumors affecting motor function, who have had recent surgery related to the motor cortex. Participants must be able to understand English, consent in writing, and follow the study's procedures. They should not be on antipsychotic meds or have a history of stroke or severe psychiatric conditions like bipolar disorder or schizophrenia.
What is being tested?
The trial is examining how well navigated repetitive transcranial magnetic stimulation (nrTMS) can help improve movement abilities that were lost due to brain tumor surgery. Patients will receive nrTMS sessions and their motor rehabilitation progress will be monitored.
What are the potential side effects?
While specific side effects are not detailed here, nrTMS is generally considered safe but may cause discomfort at the stimulation site, headache, lightheadedness, or seizures in very rare cases.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Intervention adherence
Other study objectives
Changes in cortical activity
Motor recovery

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Supportive care (nrTMS)Experimental Treatment2 Interventions
Between 1-7 days after standard of care surgery, participants undergo 10 nrTMS sessions over 30 minutes each over 3 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation
2017
Completed Phase 4
~730

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,070 Previous Clinical Trials
1,802,776 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,938 Previous Clinical Trials
41,023,138 Total Patients Enrolled
Sarah PrinslooPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
818 Total Patients Enrolled

Media Library

Transcranial Magnetic Stimulation (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT03606161 — N/A
Brain Tumor Research Study Groups: Supportive care (nrTMS)
Brain Tumor Clinical Trial 2023: Transcranial Magnetic Stimulation Highlights & Side Effects. Trial Name: NCT03606161 — N/A
Transcranial Magnetic Stimulation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03606161 — N/A
~0 spots leftby Dec 2024